Genelux Corp. (GNLX) AI Stock Analysis

• Market Cap: $245.91M
• Dividend Yield: N/A
• Average Volume (3M): 156.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.87
• Revenue Growth: -100.00%
• EPS Growth: 11.41%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 37,773,440
• 10 Day Avg. Volume: 178,540
• 30 Day Avg. Volume: 156,945
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 92.23
• Enterprise Value/Gross Profit: -139.12
• Enterprise Value/Ebitda: -2.71
• 1Y Price Target: $22.50
• Price Target Upside: 191.83% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 55 Neutral
• Price Target: $8.00 ▲(3.76% Upside)

Genelux Corp.'s stock score is primarily impacted by its weak financial performance and valuation, reflecting ongoing profitability and cash flow challenges. While technical analysis shows strong momentum, the overbought condition suggests caution. The lack of earnings call insights and corporate events further limits the score.

Positive Factors

Equity Improvement

Transitioning to positive stockholders' equity indicates improved financial health, enhancing stability and potential for future growth.

Innovative Cancer Therapies

The focus on innovative cancer therapies positions Genelux as a leader in addressing unmet medical needs, providing long-term growth potential.

Strategic Partnerships

Strategic partnerships enhance revenue streams and provide access to resources and expertise, supporting sustained business development.

Negative Factors

High Leverage

High leverage can limit financial flexibility and increase risk, potentially impacting long-term operational stability and growth.

Negative Cash Flow

Negative cash flow suggests inefficiencies in operations, posing risks to sustainability and requiring reliance on external financing.

Weak Profitability

Persistent negative profitability highlights operational challenges, limiting reinvestment capacity and affecting long-term viability.

Genelux Corp. Business Overview & Revenue Model

Company Description

Genelux Corp. (GNLX) is a biotechnology company focused on developing innovative cancer therapies using its proprietary gene therapy platform. The company specializes in oncolytic virus therapies, which are designed to selectively target and destroy cancer cells while sparing normal tissues. Genelux is advancing its lead product candidates through clinical trials, aiming to provide new treatment options for patients with various types of cancer. The company is primarily engaged in the biotechnology sector, emphasizing research and development of cutting-edge therapies that address unmet medical needs.

How the Company Makes Money

Genelux Corp. generates revenue through several key streams, primarily focused on the development and commercialization of its oncolytic virus therapies. The company earns money by conducting clinical trials and securing partnerships with pharmaceutical companies for co-development and licensing agreements. These collaborations may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory events, and royalties on future sales of successful products. Additionally, Genelux may benefit from government grants and funding aimed at supporting innovative cancer research, which can contribute to its overall financial health. The success of its pipeline products and strategic partnerships play a crucial role in the company's revenue generation.

Genelux Corp. Financial Statement Overview

Summary

Genelux Corp. faces significant financial challenges, with persistent negative profitability and cash flow issues. Despite some improvements in equity, the company remains highly leveraged, and its dependency on financing activities for cash flow sustainability poses risks, especially given the volatile nature of the biotechnology industry.

Income Statement

Genelux Corp. shows weak profitability with consistently negative net incomes over the years. The 2024 revenue growth is misleading due to the low base effect from previous years. Gross profit margin is positive due to costs being reported as negative, but net profit margin remains negative, indicating ongoing operational challenges. Both EBIT and EBITDA margins are negative, underscoring significant profitability issues.

Balance Sheet

The company has improved its equity position, transitioning from negative to positive stockholders' equity in recent years, which is a positive sign. However, the debt-to-equity ratio improved but remains concerning, reflecting high leverage. The equity ratio indicates a low percentage of assets financed by equity, limiting financial flexibility.

Cash Flow

Operating cash flows remain negative, indicating ongoing operational losses. Free cash flow is also negative, with no clear growth trajectory. The operating cash flow to net income ratio is not favorable, reflecting inefficiencies in converting income into cash. Financing activities are primarily sustaining the cash position, which poses risks if external financing becomes unavailable.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	896.00K	8.00K	170.00K	11.07M	0.00	0.00
Gross Profit	-594.00K	8.00K	-848.00K	10.10M	-895.00K	-658.00K
EBITDA	-30.46M	-28.97M	-26.46M	-1.73M	-13.67M	-11.76M
Net Income	-30.39M	-29.87M	-28.30M	-5.21M	-17.80M	-14.86M
Balance Sheet
Total Assets	32.25M	34.72M	27.89M	5.53M	8.13M	14.01M
Cash, Cash Equivalents and Short-Term Investments	27.97M	30.89M	23.19M	397.00K	4.50M	11.35M
Total Debt	1.71M	1.87M	2.52M	26.35M	25.31M	26.06M
Total Liabilities	8.35M	8.44M	8.42M	41.31M	41.24M	36.66M
Stockholders Equity	23.90M	26.27M	19.47M	-35.78M	-33.11M	-22.66M
Cash Flow
Free Cash Flow	-22.81M	-21.61M	-21.30M	-3.62M	-6.58M	-7.22M
Operating Cash Flow	-22.54M	-21.23M	-20.27M	-3.57M	-6.58M	-7.21M
Investing Cash Flow	11.52M	-8.13M	-14.72M	-49.00K	0.00	-20.00K
Financing Cash Flow	9.71M	28.51M	44.02M	-478.00K	-270.00K	18.15M

Genelux Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GNLX, the sentiment is Positive. The current price of 7.71 is above the 20-day moving average (MA) of 5.25, above the 50-day MA of 4.33, and above the 200-day MA of 3.50, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 79.82 is Negative, neither overbought nor oversold. The STOCH value of 84.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GNLX.

Genelux Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FATE	56 Neutral	$176.45M	―	-52.11%	―	-31.23%	14.92%
GNLX	55 Neutral	$245.91M	―	-98.72%	―	-100.00%	11.41%
CHRS	54 Neutral	$195.26M	-1.21	-860.65%	―	-53.67%	-330.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CRBP	43 Neutral	$217.41M	-3.65	-49.00%	―	―	18.15%
TNXP	42 Neutral	$165.50M	-0.02	-77.51%	―	-21.09%	90.95%
FBRX	36 Underperform	$144.97M	-1.51	-73.46%	―	―	62.69%

Genelux Corp. Corporate Events

Genelux Corp. Lowers Stock Option Exercise Prices

On September 1, 2025, Genelux Corporation’s Board of Directors approved a reduction in the exercise prices of certain outstanding stock options under its 2022, 2019, and 2009 Equity Incentive Plans, lowering them to $3.33 per share. This strategic move aims to retain and incentivize employees while preserving cash resources, without causing stock dilution. Additionally, on August 27, 2025, the company held its Annual Meeting of Stockholders, where key decisions included the election of Class III Directors and the ratification of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (GNLX) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Genelux Corp. stock, see the GNLX Stock Forecast page.